A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).

Joyce Liu,William T. Barry,Robert M. Wenham,Andrea E. Wahner Hendrickson,Deborah K. Armstrong,Nancy Chan,David E. Cohn,Jung-Min Lee,Richard T. Penson,Mihaela C. Cristea,James L. Abbruzzese,Koji Matsuo,Alexander B. Olawaiye,Sarah Farooq,Elizabeth M. Swisher,Eliezer M. Van Allen,Geoffrey I. Shapiro,Elise C. Kohn,S. Percy Ivy,Ursula A. Matulonis

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).

2018

5519Background: The combination of cediranib (ced) and olaparib (olap) improves progression-free survival and overall response rates (ORR) in women with recurrent plat sensitive high-grade serous (...

Keywords:

Ovarian cancer
Cediranib
Cancer research
Pathology
Olaparib
Biomarker (medicine)
Medicine
Serous fluid
Oncology
Internal medicine
overall response rate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations